Olfactory dysfunction and neuropsychiatric manifestations in early drug-naïve Parkinson’s disease
Objective: To determine the severity of various neuropsychiatric disturbances in drug-naïve Parkinson’s disease (PD) patients with (PD-OD) and without olfactory dysfunction (PD-NOD) compared to healthy…Development and Clinimetric Testing Plan for the MDS Parkinson’s Disease Psychosis Rating Scale (MDS-PDPRS)
Objective: Present the development process and clinimetric testing plan for the International Parkinson and Movement Disorder Society Parkinson's Disease Psychosis Rating Scale (MDS-PDPRS). Background: Psychosis…ER Visits and Hospitalizations Among Patients Treated with Pimavanserin or Other-AAPs for Parkinson’s Disease Psychosis: Analysis of Medicare beneficiaries
Objective: To examine health resource utilization (HRU) outcomes among PDP patients treated with PIMA vs. other AAPs. Background: Real-world analysis demonstrating pimavanserin (PIMA) benefits, the…Parkinson’s Disease, Cognition, Positive Symptoms and Medication Management
Objective: Explore the relationship between multi-domain cognitive testing and patient-reported psychiatric symptoms in PwPD to self-medication management capabilities. Background: Parkinson’s disease (PD) is a complex…Phantom boarder syndrome associated with experimentally-induced presence hallucinations in Parkinson’s disease
Objective: Measuring experimentally-induced presence hallucinations in patients with Parkinson’s disease phantom boarder phenomena. Background: Phantom boarder syndrome (PB) is described as the sensation that someone…Reduced Risk of Mortality and Antipsychotics in Parkinson’s Disease-Related Psychosis: Pimavanserin vs Off-Label Antipsychotics
Objective: Summarize the available data for the mortality risk associated with Parkinson’s disease (PD) psychosis (PDP) and pimavanserin. Background: PDP is associated with increased mortality…Parkinson’s Disease and Psychosocial Impact: Anxiety, Depression and Positive Symptoms
Objective: Explore the relationship between patient self-reported assessment of positive symptoms, depression, and anxiety in PwPD. Background: Parkinson’s disease (PD) is a complex neurodegenerative disorder…Risk of Long-term Care Admissions Among Medicare Patients Treated with Pimavanserin or Other Atypical Antipsychotics for Parkinson’s Disease Psychosis
Objective: To examine all-cause long-term care (LTC) admission risk among PDP patients treated with atypical antipsychotic (AAP). Background: Risk of LTC-admissions associated with off-label AAPs…Motor-Related and Cognition-Related Safety of Pimavanserin in Patients with Parkinson’s Disease Psychosis (PDP)
Objective: Evaluate motor- and cognition-related safety in pimavanserin-treated patients with PDP. Background: Pimavanserin, a selective 5-HT2A inverse agonist/antagonist, is the only US FDA-approved treatment for…Psychosis in Parkinson’s disease and polymorphisms of the HOMER1 and COMT genes: Is there an association?
Objective: To investigate if polymorphisms of the HOMER1 and COMT gene are associated with psychosis in Parkinson’s disease (PD). Background: Psychosis is one of the…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 12
- Next Page »